In the News

August 6, 2020
Developers of generic and biosimilar medicines support diversification of the pharmaceutical supply chain and are working with policymakers to add to our significant manufacturing presence in the United States
increasing access to biosimilars act
July 2, 2020
The Biosimilars Council commends Senators Cornyn and Bennet for the introduction of the Increasing Access to Biosimilars Act.
Key Lessons for the US From EU
June 3, 2020
A new report from Matrix Global Advisors (MGA) details “lessons learned” from the European biosimilars experience that can improve access to these medicines for America’s patients.
February 24, 2020
The Council applauds the FDA’s action and continues to call on policymakers to support legislation that would require all patents for the reference biologic to be listed in the Purple Book.
February 5, 2020
CMS’ proposal for a separate preferred specialty tier is a very welcome and significant step that will encourage greater generic and biosimilar adoption for America’s patients.
biologics market
February 3, 2020
The Biosimilars Council welcomes the FTC and FDA collaboration to promote competition in the biologics markets and bolster confidence in these medicines.

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.

SIGN UP FOR OUR NEWSLETTER